We're excited to share our new study on the role of the ABCA7 gene in brain resilience against #Alzheimer’s. Published in @CellGenomics, we found that ABCA7 is crucial for maintaining synaptic health by regulating #neuropeptide Y (NPY), a key molecule for brain communication and repair. Loss of ABCA7 reduces NPY, weakening the brain's defenses against AD. By combining #zebrafish models, human datasets, and #patient-derived iPSCs, we discovered that ABCA7 variants impact synaptic integrity and brain function. Our study also highlights how Alzheimer mechanisms mechanisms vary across different ethnicities. Understanding ABCA7's role in diverse populations can help develop more targeted and effective treatments. By targeting #ABCA7 and boosting NPY signaling, future therapies could offer better protection against AD, giving us hope for new treatment strategies. #Neurodegeneration #DiversityInResearch #HealthEquity #BrainHealth Study Shows How Common Genetic Variants in Black Americans Increase Alzheimer’s Risk

🚨We're hiring! We are looking for a Technician B at @KizilLab @ColumbiaMed. If you have lab experience and a passion for research, apply now to join our innovative team in New York City! 🔬 🐟 🔗 #JobAlert #ResearchJobs #NYCJobs #LabTech

Our review is out in @TrendsinPharma. Multi-target drugs for Alzheimer's disease "Traditional therapies aimed at single targets have fallen short owing to the complex, multifactorial nature of #Alzheimer's disease that necessitates simultaneous targeting of various #disease mechanisms for #clinical success. Therefore, targeting multiple pathologies at the same time could provide a synergistic #therapeutic effect." @KizilLab

Congratulations to the Poster Winners of the 2024 Postdoctoral Research Symposium on May 3rd!